Safinamide Methanesulfonate matching placebo

DRUG3 trials

Sponsors

Zambon SpA

Conditions

Dyskinesia, Drug-InducedIdiopathic Parkinson DiseaseMultiple System AtrophyParkinson Disease

Phase 2

Safinamide for Multiple System Atrophy (MSA)

CompletedNCT03753763

Zambon SpAMultiple System Atrophy

Start: 2019-10-29End: 2021-01-05Updated: 2021-10-13

Phase 3

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

WithdrawnNCT03987750

Zambon SpADyskinesia, Drug-Induced, Parkinson Disease

Start: 2019-10-31End: 2021-05-31Updated: 2020-06-17

Phase 4

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

CompletedNCT03841604

Zambon SpAIdiopathic Parkinson Disease

Start: 2019-04-09End: 2021-05-03Updated: 2023-05-22